 Scientists who last
year identified new gene mutations unique to colon cancers in African
Americans, have now found that tumours with these mutations are highly
aggressive and more likely to recur and metastasize.
Scientists who last
year identified new gene mutations unique to colon cancers in African
Americans, have now found that tumours with these mutations are highly
aggressive and more likely to recur and metastasize. 
Case Comprehensive Cancer
Center researchers, a research collaboration which includes University
Hospitals Seidman Cancer Center and Case Western Reserve University, who last
year identified new gene mutations unique to colon cancers in African Americans,
have found that tumors with these mutations are highly aggressive and more
likely to recur and metastasize. These findings partly may explain why African
Americans have the highest incidence and death rates of any group for this
disease.  
 The study will be
printed in the December 2016 issue of the Journal of the National Cancer
Institute (JNCI) by members
of a research team that a year ago found 15 genes in African Americans that are
rarely or never detected as mutated in colon cancers from Caucasians. The
current study investigated the outcomes associated with these mutations in
African American colorectal cancer. This study is significant because it helps
shed further light on why colorectal cancers are more aggressive in African
Americans.
The study will be
printed in the December 2016 issue of the Journal of the National Cancer
Institute (JNCI) by members
of a research team that a year ago found 15 genes in African Americans that are
rarely or never detected as mutated in colon cancers from Caucasians. The
current study investigated the outcomes associated with these mutations in
African American colorectal cancer. This study is significant because it helps
shed further light on why colorectal cancers are more aggressive in African
Americans. The researchers examined 66 patients who had stage I -- III colorectal cancer and found those patients positive for the mutations had an almost three times higher rate of metastatic disease, and stage III patients positive with mutations were nearly three times more likely to relapse compared to patients without the mutations.
Source:
science daily
 
No comments:
Post a Comment